Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

Completed

• Conditions: Peritonitis

• Registration Number: NCT00481962
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2007-05-31
• Study First Submitted QC: 2007-06-01
• Study First Posted: 2007-06-04
• Primary Completion: 2008-12
• Study Completion: 2008-12
• Status Verified: 2009-09
• Last Update Submitted: 2009-09-25
• Last Update Posted: 2009-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Diagnosis of secondary peritonitis
• Treatment in an ICU
• Patient age >18 years

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified